| Variable |
n |
% |
Range |
Median |
| Age (years) |
|
|
47-83 |
68.7 |
| iPSA (ng/ml) |
|
|
4.1-175.0 |
24.2 |
| GS |
|
|
6-9 |
7 |
| Follow up (Months) |
|
|
24-123 |
62.4 |
| Last PSA |
|
|
0.01-99.7 |
3.4 |
| Ethnicity |
|
|
|
|
| Asiatic |
17 |
7.4 |
|
|
| White |
181 |
79.0 |
|
|
| Black |
18 |
7.9 |
|
|
| Mulatto |
13 |
5.7 |
|
|
| Clinical Stage |
|
|
|
|
| T1 |
89 |
38.9 |
|
|
| T2a |
71 |
31.0 |
|
|
| T2b |
32 |
14.0 |
|
|
| T3 |
37 |
16.2 |
|
|
| Neo HT |
|
|
|
|
| No |
123 |
53.7 |
|
|
| Yes |
106 |
46.3 |
|
|
| Adj HT |
|
|
|
|
| No |
56 |
24.5 |
|
|
| Yes |
173 |
75.5 |
|
|
| Risk Group |
|
|
|
|
| Intermediate |
117 |
51.1 |
|
|
| High |
112 |
48.9 |
|
|
| Total |
229 |
100.0 |
|
|
iPSA: Initial PSA Value; GS: Geason Score; IR: Intermediate Risk; HR: High
Risk; Neo HT: Neoadjuvant Androgen Deprivation; Adj HT: Adjuvant Androgen
Deprivation |
